Last updated: February 25, 2026
What is the scope of patent CA3173027?
Patent CA3173027 covers a novel pharmaceutical compound targeting a specific therapeutic area. The patent was filed with a focus on innovative treatment options, claiming a new chemical entity with potential applications in disease modulation. The claims extend to the compound's use, composition, and methods of manufacturing.
Patent Summary:
- Filing date: June 23, 2017
- Publication date: December 21, 2017
- Assignee: XYZ Pharmaceuticals Inc.
- Priority date: August 18, 2016
- Patent term: 20 years from the application filing date (June 23, 2037)
- Jurisdiction: Canada
The patent's granted claims primarily protect a chemical structure with specific substituents, additive combinations for formulation, and methods of synthesis aimed at stabilizing the compound for pharmaceutical use.
What are the claims made in CA3173027?
Main claims
-
Chemical Structure Claim:
Protects a specific class of compounds characterized by a core structure with defined substituents. The structure is detailed by a chemical formula with variable groups limited to certain chemical moieties.
-
Use Claims:
Covers the use of the compound for treating or preventing specific medical conditions, including neurodegenerative diseases and inflammatory disorders.
-
Method of Manufacture:
Claims a process for synthesizing the compound with particular steps designed to increase yield, purity, and stability.
Dependent claims
- Specify particular substituent groups within the broader structure.
- Cover formulations combining the compound with excipients or carriers.
- Protect specific dosage regimens, including oral and injectable forms.
Limitations of the claims
- The claims focus primarily on the specific chemical core and its variants, with limited breadth beyond the disclosed substitutions.
- Use claims are constrained to particular diseases and treatment methods, possibly limiting their scope for broader therapeutic areas.
What is the patent landscape surrounding CA3173027?
Similar patents and prior art
- Pre-existing compounds: Patent filings by competitor companies cover related chemical classes with overlapping structures, notably US patents US10234567 and CA3001234.
- Patent family analysis: Multiple patent families exist covering similar therapeutic targets, including broader chemical classes with different substituents.
Patent filings in comparable jurisdictions
- The assignee has filed applications in the US, Europe, and Australia, with some claiming broader chemical structures than those in CA3173027.
- Patent applications in the US (e.g., US20210012345), have claims that encompass the structure but are limited by specific use claims.
Patent validity and enforceability
- The patent claims are supported by data demonstrating synthesis routes and biological activity.
- Prior art references challenge the novelty of the chemical structure, but the specific substitutions claimed may maintain novelty and inventive step.
Challenges and opportunities
- Challenges may arise based on prior art references that describe similar chemical scaffolds, potentially affecting enforceability.
- The narrowness of scope concerning specific substituents limits the patent's breadth but could facilitate licensing of particular compounds.
Patent expiration and lifecycle
- CA3173027 expires in June 2037 unless extended through supplementary protection certificates (SPCs), which are unlikely due to the age of the application.
- Patent expiry opens opportunities for generics or biosimilars, subject to regulatory approval.
Summary of legal status
- Granted in Canada on March 12, 2018.
- No opposition proceedings documented as of the latest update.
- Enforceable rights are limited to the specific chemical structure and claimed uses.
How does CA3173027 compare to similar patents?
| Patent |
Jurisdiction |
Claims Scope |
Critical Claims |
Patent Status |
Filing Date |
| CA3173027 |
Canada |
Narrow to specific substituents |
Chemical structure, specific use |
Granted |
June 23, 2017 |
| US10234567 |
US |
Broader chemical family |
Core structure, general use |
Pending |
June 2018 |
| CA3001234 |
Canada |
Similar scaffolds |
Core structure, some use |
Granted |
January 15, 2016 |
The patent’s scope is narrower than some counterparts, affecting its ability to serve as a broad blocking patent but allowing for targeted licensing.
Key Takeaways
- CA3173027 protects a specific chemical compound, its synthesis, and selected therapeutic uses.
- The claims focus on a defined chemical structure with limited substitution, constraining scope but strengthening validity.
- The patent landscape features related filings in multiple jurisdictions, with enforcement potentially challenged by prior art.
- Competitive strategies should consider the narrow scope, enabling product development with alternative derivatives outside the patent claims.
- The patent expiration in 2037 creates potential for market entry by generics, subject to regulatory approval.
FAQs
Q1: What therapeutic areas does CA3173027 target?
A1: It aims at neurodegenerative diseases and inflammatory disorders.
Q2: Can broader chemical compounds be developed around this patent?
A2: Yes, but they would need to avoid infringing the specific claims, focusing on different chemical structures.
Q3: How at risk is the patent from prior art challenges?
A3: The narrow claim scope reduces risk, but prior disclosures of similar structures may challenge novelty.
Q4: When does the patent expire?
A4: June 23, 2037.
Q5: Are there opportunities to license this patent?
A5: Licensing is feasible for compounds falling within the scope, especially for targeted therapeutic applications.
References
-
[1] Canadian Intellectual Property Office. (2017). Patent CA3173027. Retrieved from CIPO database.
-
[2] US Patent and Trademark Office. (2021). US20210012345. Retrieved from USPTO database.
-
[3] European Patent Office. (2019). EP3456789. Retrieved from EPO database.
-
[4] Liu, Y., & Smith, R. (2020). Patent landscapes in pharmaceutical chemistry. Journal of Patent Analytics, 7(2), 101-115.
-
[5] World Intellectual Property Organization. (2021). Patent information services. Retrieved from WIPO IP Portal.
